JP Morgan Maintains Neutral Rating and $94 PT on LabCorp

A report from J.P. Morgan reiterates its Neutral rating and $94 price target on LabCorp LH. The report states, “We note that Genzyme pricing appears to have actually increased in 2Q see Table 1. We estimate pricing to decline significantly in 2H11, yet our estimates project ~660 bps contribution to overall revenue growth and we believe there is potential for upside if either pricing remains higher than expected and/or volumes are greater”. LH closed yesterday at $78.76.